-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On October 12, Yehui Pharmaceutical announced that it had signed a licensing agreement with Sutro Biopharma.
According to the agreement, Yehui Pharmaceutical can choose to obtain the exclusive right to develop and commercialize STRO-001 in Greater China
Yehui Pharmaceuticals will pay Sutro a down payment of US$4 million, with potential payments related to option exercise, drug development, registration and commercial milestones totaling up to US$200 million
CD74 is expressed in a variety of blood cancers, and the drug-antibody ratio of STRO-001 is 2
In the United States, Sutro is exploring STRO-001 as a treatment for advanced patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma, mantle cell lymphoma, and follicles Lymphoma
Note: The original text has been deleted